The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

被引：8

作者：

Sofia, M. Anthony ^{[1
]}

Rubin, David T. ^{[1
]}

机构：

[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, 5841 South Maryland Ave,MC 4076, Chicago, IL 60637 USA

来源：

DIGESTIVE DISEASES AND SCIENCES | 2017年 / 62卷 / 04期

关键词：

Therapeutic antibodies; Tumor necrosis factor alpha; Infliximab; Inflammatory bowel disease; Therapeutic drug monitoring; Adalimumab; ANTITUMOR NECROSIS FACTOR; INFLAMMATORY-BOWEL-DISEASE; LIVER-TRANSPLANT RECIPIENTS; CERTOLIZUMAB PEGOL CDP870; PLACEBO-CONTROLLED TRIAL; ANTI-TNF-ALPHA; CROHNS-DISEASE; MONOCLONAL-ANTIBODY; MAINTENANCE THERAPY; ULCERATIVE-COLITIS;

D O I：

10.1007/s10620-017-4479-0

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn's disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

引用

页码：833 / 842

页数：10

共 119 条

[1] Open-Label Study of Adalimumab in Patients with Ulcerative Colitis Including Those with Prior Loss of Response or Intolerance to Infliximab [J].

Afif, Waqqas ;

Leighton, Jonathan A. ;

Hanauer, Stephen B. ;

Loftus, Edward V., Jr. ;

Faubion, William A. ;

Pardi, Darrell S. ;

Tremaine, William J. ;

Kane, Sunanda V. ;

Bruining, David H. ;

Cohen, Russell D. ;

Rubin, David T. ;

Hanson, Karen A. ;

Sandborn, William J. .

INFLAMMATORY BOWEL DISEASES, 2009, 15 (09) :1302-1307

[2] Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis [J].

Ananthakrishnan, Ashwin N. ;

Cagan, Andrew ;

Cai, Tianxi ;

Gainer, Vivian S. ;

Shaw, Stanley Y. ;

Savova, Guergana ;

Churchill, Susanne ;

Karlson, Elizabeth W. ;

Kohane, Isaac ;

Liao, Katherine P. ;

Murphy, Shawn N. .

INFLAMMATORY BOWEL DISEASES, 2016, 22 (04) :880-885

[3]

Ananthakrishnan AN, 2013, INFLAMM BOWEL DIS, V19, P37, DOI [10.1097/MIB.0b013e3182902ad9, 10.1002/ibd.22951]

[4] Clostridium difficile infection: epidemiology, risk factors and management [J].

Ananthakrishnan, Ashwin N. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (01) :17-26

[5] Fecal MMP-9: A New Noninvasive Differential Diagnostic and Activity Marker in Ulcerative Colitis [J].

Annahazi, Anita ;

Molnar, Tamas ;

Farkas, Klaudia ;

Rosztoczy, Andras ;

Izbeki, Ferenc ;

Gecse, Krisztina ;

Inczefi, Orsolya ;

Nagy, Ferenc ;

Foeldesi, Imre ;

Szucs, Monika ;

Dabek, Marta ;

Ferrier, Laurent ;

Theodorou, Vassilia ;

Bueno, Lionel ;

Wittmann, Tibor ;

Roka, Richard .

INFLAMMATORY BOWEL DISEASES, 2013, 19 (02) :316-320

[6] An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis [J].

Assa'ad, Amal H. ;

Gupta, Sandeep K. ;

Collins, Margaret H. ;

Thomson, Mike ;

Heath, Amy T. ;

Smith, Deborah A. ;

Perschy, Teresa L. ;

Jurgensen, Cynthia H. ;

Ortega, Hector G. ;

Aceves, Seema S. .

GASTROENTEROLOGY, 2011, 141 (05) :1593-1604

[7] In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease [J].

Atreya, Raja ;

Neumann, Helmut ;

Neufert, Clemens ;

Waldner, Maximilian J. ;

Billmeier, Ulrike ;

Zopf, Yurdaguel ;

Willma, Marcus ;

App, Christine ;

Muenster, Tino ;

Kessler, Hermann ;

Maas, Stefanie ;

Gebhardt, Bernd ;

Heimke-Brinck, Ralph ;

Reuter, Eva ;

Doerje, Frank ;

Rau, Tilman T. ;

Uter, Wolfgang ;

Wang, Thomas D. ;

Kiesslich, Ralf ;

Vieth, Michael ;

Hannappel, Ewald ;

Neurath, Markus F. .

NATURE MEDICINE, 2014, 20 (03) :313-318

[8] Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis [J].

Baert, F. ;

Vande Casteele, N. ;

Tops, S. ;

Noman, M. ;

Van Assche, G. ;

Rutgeerts, P. ;

Gils, A. ;

Vermeire, S. ;

Ferrante, M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (11-12) :1324-1332

[9] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[10] Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial [J].

Baert, Filip ;

Kondragunta, Venkateswarlu ;

Lockton, Steven ;

Casteele, Niels Vande ;

Hauenstein, Scott ;

Singh, Sharat ;

Karmiris, Konstantinos ;

Ferrante, Marc ;

Gils, Ann ;

Vermeire, Severine .

GUT, 2016, 65 (07) :1126-1131

← 1 2 3 4 5 6 7 8 9 10 →